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INTRODUCTION
Chronic hepatitis B (CHB) can lead to a range of diseases from 
asymptomatic status to the development of liver cirrhosis or hepa-
tocellular carcinoma (HCC). Elevated serum levels of hepatitis B 
virus (HBV)-DNA are associated with an increased risk of this 
spectrum of diseases.1-4 Long-term suppression of HBV-DNA using 
potent nucleos(t)ide analogues (NA) with high genetic barriers is 
required to reduce the risk of disease progression in CHB patients 
who are in the hepatitis B e-antigen (HBeAg)-positive or HBeAg-
negative immune-active (IA)-phase.5-9
Chronic HBV infection has been divided into several phases, in-
cluding immune-tolerant (IT)-phase, immune inactive (IIA)-phase, 
and an IA-phase, which requires antiviral therapy (AVT).5,10,11 Of 
these, the IT-phase, also known as HBeAg-positive chronic HBV 
infection, is characterized by the presence of HBeAg, high levels 
Background/Aims: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative 
of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase 
stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT.
Methods: Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, 
with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of <1.45 were classified into the 
IT-group. The cumulative probability of HCC was estimated using Kaplan-Meier analysis. All patients were assessed until 
HCC development (intention-to-treat [ITT] analysis), whereas those suspected of experiencing CHB phase switch were 
assessed using the per-protocol (PP) and censored at the time of phase switch.
Results: The cumulative probability of HCC at 1-, 3-, and 5-years among the IT-group was zero, compared to AVT-treated 
patients with FIB-4 indices <1.45 during the same period: 0.2%, 0.6%, and 1.4%, respectively (P=0.264 for ITT and 
P=0.533 for PP). Among the initially screened 125 untreated patients, those with a FIB-4 index of ≥1.45 had a higher risk 
of HCC compared to the IT-group (P=0.005). Furthermore, among AVT-treated patients, those with a FIB-4 index of ≥1.45 
had a higher risk of HCC compared to their counterpart (P<0.001).
Conclusions: The risk of HCC was negligible in the IT-group stringently defined by a low FIB-4 index. However, given that 
a higher HCC risk exists among untreated patients with higher FIB-4, appropriate criteria for AVT should be established. 
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study showed negligible risk of HCC in IT phase patients with a pre-defined low FIB-4 index, thus, an early antiviral intervention should be carefully 
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of HBV-DNA (>106–107 IU/mL), a normal range of alanine amino-
transferase (ALT) levels, and minimal or no necroinflammation. 
Thus, in spite of the high viral load, AVT is not generally recom-
mended for patients with IT-phase due to the low risk of disease 
progression and HCC development.5,10-12
However, several studies have suggested the possibility of im-
mune responses for patients with IT-phase, proposing the risk of 
hepatocarcinogenesis.2,13-16 The high level of HBV-DNA integration 
and clonal hepatocyte expansion observed during the IT-phase 
demonstrated that it may be an early stage in which high replica-
tive and low inflammatory activities occur, suggesting HCC risk 
and disease progression.13 In addition, a recent study by Kim et 
al.17 suggested that earlier AVT might be required for a certain 
proportion of patients with IT-phase, based on the results that the 
untreated patients with IT-phase that lasted for at least 1 year 
showed an increased risk of HCC, and mortality or liver transplan-
tation, compared with patients treated using AVT. However, in 
this study, patients that had IT-phase for 1-year, were selected re-
gardless of the phase afterwards, which might result in the het-
erogeneity of the population with IT-phase. Therefore, it has not 
been fully confirmed whether the long-term outcomes of patients 
with IT-phase are unfavorable.12,18,19 Furthermore, a recent multi-
center study reported contradictory results that the risk of HCC 
development is extremely low in patients with CHB in IT-phase.20
Thus, we aimed to compare the risk between patients develop-
ing HCC in the IT-phase and those undergoing AVT through inten-
tion-to-treat (ITT) and per-protocol (PP) analyses. In addition, we 
investigated whether the HCC development could differ depend-
ing on the fibrosis-4 (FIB-4) index, an indicative marker of poten-
tial liver damage and fibrosis, among both untreated patients 




For the current study, consecutive CHB patients were recruited 
from 2012 to 2018. Infection was considered as CHB for patients 
who tested positive for the hepatitis B s antigen for more than 
6 months.5,11 Among untreated patients with positive HBeAg, 
HBV-DNA levels were >20,000 IU/mL with normal ALT levels (un-
treated patients belonging to the IT-phase),5,10,11 we defined a 
subgroup with an FIB-4 index of <1.45 as belonging to IT-phase 
(IT-group),21 considering their minimal fibrotic burden and excel-
lent prognosis. ALT levels of <40 IU/L were defined as normal ac-
cording to clinical guidelines developed by the Korean Association 
for the Study of the Liver (KASL).5,11 Patients undergoing AVT in-
cluded those who had already received AVT during enrollment or 
those who had begun AVT within three months according to the 
treatment guidelines developed by KASL,11 and the reimbursement 
guidelines of the national health insurance program of the Repub-
lic of Korea. Likewise, among patients undergoing AVT, we de-
fined a subgroup with a FIB-4 index of <1.45 as the AVT-group.
Exclusion criteria included the following: 1) untreated minimal 
active status or IIA-phase;22,23 2) negative for hepatitis e-antigen; 
3) liver cirrhosis; 4) co-infection with hepatitis C virus; 5) prior his-
tory of decompensation, HCC, or liver transplantation; 6) signifi-
cant alcohol consumption (daily intake of more than 60 g of alco-
hol in men and 20 g of alcohol in women);24,25 7) development of 
HCC within 6 months after enrollment; and 8) follow-up duration 
of <12 months (Supplementary Fig. 1). Cirrhosis was defined as 
the presence of a coarse liver echo texture or nodular liver surface 
on sonography. Fatty liver was also diagnosed using sonography. 
FIB-4 index was calculated using the following formula: [age 
(years) × aspartate aminotransferase (AST; IU/L)] / [platelet (109/L) 
× ALT (IU/L)1/2]. Among the cutoff values suggested in previous 
studies, we used 1.45 as the cutoff for FIB-4 index.21,26
The study protocol was in accordance with the ethics guidelines 
of the 1975 Declaration of Helsinki and the study was approved 
by the Institutional Review Board of Severance Hospital. Informed 
consent from patients was waived due to the retrospective nature 
of this cohort study.
CHB phase switch among patients with IT-phase 
Although the majority of the IT-group were expected to main-
tain a virological phase during the course of the study period, a 
phase switch from IT-phase into IA-phase requiring AVT, IIA-
phase, or minimally active CHB phase might have been experi-
enced. A phase switch was confirmed when the pre-switch phase 
lasted for at least 6 months. HCC development was monitored us-
ing ITT analysis, whereas PP analysis was used for patients who 
experienced a phase switch and were censored at the time of 
phase switch during the follow-up period.
Follow-up assessments and the primary end-point
Patients received regular assessments of serum aminotransfer-
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ase, serologic markers (e.g., HBeAg and anti-HBe), HBV-DNA lev-
els, alpha-fetoprotein, and sonography every 3–6 months.11 The 
follow-up periods for each patient were calculated from the date 
of enrollment to the date of developing HCC, and mortality.
The cumulative probabilities of HCC and Cox proportional haz-
ard ratio were calculated during the follow-up period. The diag-
nosis of HCC was based on typical features of nodules (>1 cm) 
with arterial enhancement and a portal/delayed phase washout 
through dynamic computed tomography and/or magnetic reso-
nance images, as well as elevated tumor marker, and/or histologi-
cal examination.11
Statistical analysis
Baseline characteristics are expressed as the median (interquar-
tile range [IQR]) or number (%) as appropriate. The Mann-Whit-
ney test or chi-squared test (Fisher’s exact test) was used to com-
pare characteristics between two groups. In addition, the Cox 
proportional hazard model was used for uni- and multivariate 
analyses.
Cumulative probabilities of HCC development were estimated 
using the Kaplan-Meier method. A value of P<0.05 was an indi-
cation of statistical significance. Multivariate analysis was per-
formed using variables with a P-value of <0.1 in univariate analysis. 
Data was analyzed using the statistical package for the social sci-
ences (SPSS) ver. 25.0 for Windows (IBM Corp., Armonk, NY, USA).
RESULTS
Baseline characteristics of the entire study 
population
Based on enrollment criteria, a total of 2,149 patients were fi-
nally analyzed. The baseline characteristics of the study popula-
tion are summarized in Table 1. The median age of the entire 
study population was 46.7 (IQR, 36.2–55.6) years and 887 
(41.3%) of the patients were male. When initially screened, 125 
(5.8%) untreated patients with positive HBeAg, HBV-DNA levels 
of >20,000 IU/mL with normal ALT levels (untreated patients be-
longing to the IT-phase), were compared with 2,024 (94.2%) pa-
tients undergoing AVT. The former was significantly younger (me-
dian 38.6 vs. 47.2 years; P<0.05) and more likely to be male than 
the latter (61.6% vs. 40.0%; P<0.05). The proportion of diabetes 




Untreated patients belonging 





Age (years) 46.7 (36.2–55.6) 38.6 (28.1–50.7) 47.2 (37.0–55.8) <0.001
Male gender 887 (41.3) 77 (61.6) 810 (40.0) <0.001
Fatty liver 295 (13.7) 16 (12.8) 279 (13.8) 0.756
Diabetes mellitus 268 (12.5) 7 (5.6) 261 (12.9) 0.017
Hypertension 413 (19.2) 18 (14.4) 395 (19.5) 0.159
Laboratory variables
Platelet counts (109/L) 195 (153–241) 210 (179–262) 193 (151–240) 0.029
Total bilirubin (mg/dL) 0.7 (0.5–1.0) 0.7 (0.5–0.9) 0.7 (0.5–1.0) <0.01
Serum albumin (g/L) 4.3 (3.9–4.5) 4.4 (4.1–4.6) 4.2 (3.9–4.5) <0.001
Aspartate aminotransferase (IU/L) 40 (22–88) 23 (19–27) 44 (23–91) <0.001
Alanine aminotransferase (IU/L) 46 (22–118) 23 (19–31) 53 (22–127) <0.001
Serum creatinine (mg/dL) 0.82 (0.69–0.97) 0.82 (0.68–0.96) 0.82 (0.69–0.97) 0.632
Alpha-fetoprotein (ng/mL) 3.46 (2.19–7.72) 1.88 (1.38–3.60) 3.56 (2.30–8.19) 0.280
HBV-DNA (log IU/mL) 5.43 (2.46–7.83) 8.04 (7.82–8.04) 5.10 (2.23–7.53) <0.001
Fibrosis-4 index 1.49 (0.88–2.56) 0.84 (0.57–1.39) 1.53 (0.91–2.62) <0.001
Values are presented as median (interquartile range) or number (%).
IT, immune-tolerant; AVT, antiviral therapy; HBV, hepatitis B virus.
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Age (years) 40.8 (32.1–49.8) 34.4 (27.4–44.7) 41.1 (32.4–50.1) <0.001
Male gender 650 (63.8) 37 (40.7) 613 (66.1) <0.001
Fatty liver 169 (16.6) 13 (14.3) 156 (16.8) 0.537
Diabetes mellitus 97 (9.5) 3 (3.3) 94 (10.1) 0.034
Hypertension 152 (14.9) 8 (8.8) 144 (15.5) 0.086
Laboratory variables
Platelet counts (109/L) 231 (198–274) 229 (200–270) 232 (198–275) 0.289
Total bilirubin (mg/dL) 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.7 (0.5–0.9) 0.279
Serum albumin (g/L) 4.4 (4.1–4.6) 4.5 (4.1–4.7) 4.4 (4.1–4.6) 0.035
Aspartate aminotransferase (IU/L) 25 (19–44) 21 (19–25) 26 (19–47) <0.001
Alanine aminotransferase (IU/L) 31 (18–80) 23 (18–31) 33 (18–84) <0.001
Serum creatinine (mg/dL) 0.84 (0.70–0.98) 0.80 (0.68–0.94) 0.85 (0.70–0.99) 0.460
Alpha-fetoprotein (ng/mL) 2.53 (1.87–3.95) 1.80 (1.27–2.95) 2.59 (1.93–4.03) 0.253
HBV-DNA (log IU/mL) 4.64 (1.83–7.90) 8.04 (7.87–8.04) 3.95 (1.63–7.25) <0.001
FIB-4 index 0.87 (0.63–1.10) 0.71 (0.47–1.02) 0.88 (0.64–1.11) <0.001
Values are presented as median (interquartile range) or number (%).
IT, immune-tolerant; AVT, antiviral therapy; FIB-4, fibrosis-4; HBV, hepatitis B virus.
Table 3. Independent predictors of HCC in subgroup with FIB-4 <1.45 (n=1,019)
Variable
Univariate Multivariate
P-value HR 95% CI P-value
Demographic variables
Age (years) 0.019 1.071 1.005–1.142 0.034
Male gender 0.285 - - -
Fatty liver 0.329 - - -
Diabetes mellitus 0.912 - - -
Hypertension 0.634 - - -
Laboratory variables - - -
Platelet counts (109/L) 0.819 - - -
Total bilirubin (mg/dL) 0.709 - - -
Serum albumin (g/L) 0.053 0.613 0.191–1.968 0.410
Aspartate aminotransferase (IU/L) 0.316 - - -
Alanine aminotransferase (IU/L) 0.118 - - -
Serum creatinine (mg/dL) 0.067 1.142 0.944–1.382 0.172
Alpha-fetoprotein (ng/mL) 0.959 - - -
HBV-DNA (log IU/mL) 0.319 - - -
AVT-group vs. IT-group 0.471 - - -
HCC, hepatocellular carcinoma; FIB-4, fibrosis-4; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; AVT, antiviral therapy; IT, immune-tolerant.
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mellitus was significantly lower in untreated patients belonging to 
IT-phase than those undergoing AVT (5.6% vs. 12.9%; P<0.001). 
In addition, the untreated patients belonging to the IT-phase had 
significantly higher platelet counts (median, 210 vs. 193 ×109/L), 
higher serum albumin level (median, 4.4 vs. 4.2 g/L), lower AST 
(median, 23 vs. 44 IU/L) and ALT levels (median, 23 vs. 53 IU/L), 
and higher HBV-DNA level (median, 8.04 vs. 5.10 log IU/mL) than 
the patients undergoing AVT (all P<0.05).
Among untreated patients belonging to the IT-phase, 63.2% of 
patients who were in the IT-phase at enrollment experienced a 
phase switch into the IA-phase during the follow-up period. The 
median follow-up period of the entire study population was 59.4 
months (IQR, 30.9–93.0) (86.7 [IQR, 55.8–11.07] in untreated 
patients belonging to the IT-phase and 57.8 [IQR, 30.3–91.3] in 
patients undergoing AVT, respectively).
Baseline characteristics of the subgroups with FIB-4 
<1.45
Among untreated patients belonging to the IT-phase and those 
undergoing AVT, we identified the IT-group and AVT-group using 
FIB-4 index <1.45. We also compared the baseline characteristics 
of the IT-group and AVT-group including, age, gender, the pres-
ence of diabetes mellitus, serum albumin, AST, ALT, and HBV-
DNA level which were significantly different between the IT-group 
and the AVT-group (P<0.05) (Table 2).
Figure 1. Cumulative probability of HCC for the IT-group and AVT-group. (A) ITT analysis and (B) PP analysis. HCC, hepatocellular carcinoma; AVT, anti-
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Figure 2. Cumulative probability of HCC according to FIB-4 scores for 
untreated patients belonging to IT-phase. HCC, hepatocellular carcino-
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Figure 3. Cumulative probability of HCC according to FIB-4 scores for 
patients undergoing AVT. HCC, hepatocellular carcinoma; FIB-4, fibro-
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Independent predictors of HCC in patients with FIB-
4 <1.45
Univariate analysis indicated that older age significantly affect-
ed HCC development (P=0.019). However, overall the AVT-group 
(vs. IT-group) were not significantly associated with the risk of 
HCC development (P=0.471). Multivariate using these variables, 
showed that older age was a significantly independent predictor 
of HCC (Table 3). By contrast, another multivariate analysis 
showed age, male gender, the presence of diabetes mellitus, low 
platelet counts, and low albumin level as independent predictors 
of HCC development in the subgroup with FIB-4 >1.45 (Supple-
mentary Table 1).
Cumulative probabilities of HCC
According to ITT and PP analysis, the cumulative probability of 
HCC at 1-, 3-, and 5-years were 0.2%, 0.6%, and 1.4% in the 
AVT-group, respectively, whereas the cumulative probability of 
HCC was zero in IT-group at the respective years. However, the 
cumulative probability for HCC development was not statistically 
different between the IT-group and AVT-group ITT and PP analy-
sis (P>0.05) (Fig. 1).
Among the untreated patients belonging to the the IT-phase, 
the cumulative probability of HCC in those with FIB-4 ≥1.45 were 
significantly higher than those with FIB-4 <1.45 (P=0.005) (Fig. 2). 
In these patients, the cumulative probability of HCC was zero for 
the subgroup with FIB-4 <1.45, whereas, 0.0% at 1-year, 6.0% 
at 3 years, and 6.0% at 5 years was recorded for patients with 
FIB-4 ≥1.45, respectively.
Among patients undergoing AVT, the subgroup with FIB-4 
≥1.45 were at a significantly higher risk of HCC compared to 
those with FIB-4 <1.45 (P<0.001) (Fig. 3). We presented the cu-
mulative probabilities of the following three groups in Supplemen-
tary Figure 2; IT-group (n=91), AVT-group (n=928) (stringently 
defined by a low FIB-4 index), and patients undergoing AVT with 
high FIB-4 (n=1,052) (overall P<0.001). In addition, the cumula-
tive probabilities of HCC development were not significantly dif-
ferent, when we further categorized the subjects into three 
groups according to their HBV-DNA levels; patients with HBV-
DNA level of <20,000 IU/mL, 20,000–10,000,000 IU/mL, and 
>10,000,000 IU/mL (overall P=0.852) (Supplementary Fig. 3).
Distribution of FIB-4 scores in untreated patients 
belonging to the IT-phase and those underoing AVT
Among the untreated patients belonging to the IT-phase, the 
patients with HCC development showed a higher distribution of 
FIB-4 scores than those without HCC development (P=0.195) 
(Fig. 4A). Furthermore, among the patients undergoing AVT, pa-
tients with HCC development had a significantly higher distribu-
tion of FIB-4 scores than those without HCC development 
(P=0.003) (Fig. 4B).
DISCUSSION
According to the American Association for the Study of Liver 
Diseases (AASLD), the European Association for the Study of the 
Liver, or KASL guidelines, the IT-phase is indicated by presence of 
serum HBeAg, elevated HBV-DNA levels (typically >1 milion IU/mL), 
normal ALT level (<30–40 IU/L for males and <19–40 IU/mL for 
females), and/or biopsies without signs of inflammation or fibro-
sis.5,10,11 All these guidelines advise against starting AVT for pa-
Figure 4. Distribution of FIB-4 score depending on HCC development among patients belonging to the IT-phase (A) and those undergoing AVT (B). 
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tients in the IT-phase of CHB.
A recent study insisted that earlier AVT intervention may reduce 
the risk of liver fibrosis and disease progression in patients in the 
IT-phase based on the findings of higher incidences of liver-relat-
ed events in untreated patients when compared to patients un-
dergoing AVT.13,17,27 In contrast, another large multicenter study 
showed that CHB patients in the IT-phase had an extremely low 
incidence of HCC development, even though patients experienced 
phase switchs that may have potentiallly increased the risk of HCC 
development during the long-term.20 Furthermore, a clinical trial 
where tenofovir disoproxil fumarate (TDF) and TDF plus emtric-
itabine was administed to patients for 4 years showed a high rate 
of relapse after NA cessation in patients in the IT-phase, and their 
natural history, such as their HBeAg seroconversion rates, did not 
change.28 That is, there were still unresolved issues such as a po-
tential harm, medical cost, and long-term safety of drug uses, as 
well as a lack of evidence indicating that AVT in patients in the IT-
phase is beneficial in reducing rates of liver-related events.
In our study, after excluding the patients with cirrhosis or a FIB-
4 score of ≥1.45 (a high risk of liver-related events), the cumula-
tive probability of HCC development in the IT-group was lower 
than that of the AVT-group, but the difference was not statistical-
ly significant. These findings suggest that early AVT intervention 
to prevent disease progression should be carefully weighed for 
untreated patients usually referred as IT-phase without significant 
fibrosis, because the clinical evidence of liver disease progression 
can not be established in these patients. Furthermore, early AVT 
intervention might raise challenges such as the socioeconomic 
burden and unintended risks of adverse influences of AVT such as 
bone loss or renal insufficiencies.29 In addition, we identified the 
low risk of HCC development in patients undergoing AVT without 
significant liver fibrosis, which is supported by recent studies.30
Our study had several advantages that strengthen its clinical 
implications. First, our study focused on long-term prognosis dur-
ing the period of IT-phase. The cumulative probability of HCC de-
velopment had no significant difference between the IT-group 
and AVT-group, irrespective of ITT or PP analysis. The conflicting 
results from a previous study17 showed favorable clinical outcomes 
for patients undergoing AVT compared to untreated CHB patients. 
Therefore, it would be premature to affirm a high risk of disease 
progression and the need for early AVT intervention in patients 
with IT-phase.
Second, in the comparison of subgroups according to the FIB-4 
index, no one experienced HCC development in the IT-group, 
whereas three patients developed HCC in the FIB-4 ≥1.45 among 
untreated patients belonging to the IT-phase. This result indicates 
that if patients have a higher fibrotic burden, even though pa-
tients are expected to have a low risk of necroinflammation, the 
risk of HCC development might be increased. However, it is diffi-
cult to determine whether inflammation or fibrosis in the liver in-
dicates potent disease progression.17 Persistently normal ALT lev-
els which are required to determine the IT-phase are not always 
consistent with signs of fibrosis or inflammation.2,14,31 Thus, when 
we are uncertain if patients in the IT-phase require treatment or 
not. However, other assessments for fibrosis, such as the FIB-4 
score or pathology tests may allow for detection of advanced fi-
brosis for early AVT intervention.5,10 It is thus not confirmed 
whether AVT should be started at the time of phase switch or 
whether AVT should be considered earlier for patients who are 
anticipated to experience a phase switch or disease progression. 
In addition, future studies should focus on establishing the criteria 
for selecting the optimal candidates for early AVT intervention 
among untreated patients belonging to IT-phase.
Thirdly, our study had a relatively long-term follow-up period 
(median, 59.4; IQR, 30.9–93.0 months). This might have in-
creased the statistical influence of our study and enabled us to in-
vestigate and compare long-term outcomes of patients with IT-
phase to that of patients undergoing AVT. However, because the 
sample size of the untreated patients belonging to the IT-phase 
was small, a large multicenter study is warranted to validate our 
results.
We are also aware of several limitations in our study. First, be-
cause no histological information was available, there is a possi-
bility that some patients with significant fibrosis or inflammation 
might have been incorporated with the untreated patients be-
longing to the IT-phase in our study. Despite this pitfall, after ex-
cluding patients with a higher fibrotic burden, there was no evi-
dence of HCC development in the IT-group during follow-up 
period. Thus, if patients with little fibrosis were selected, a more 
favorable long-term prognosis would have been anticipated, 
which might support our results.
Secondly, we selected untreated patients who had various 
ranges from very high levels of HBV-DNA to ≥20,000 IU/mL 
according to guidelines.5,10,11 It is known that levels of >6–8 log 
IU/mL of HBV-DNA are considered a lower risk of HCC, while lev-
els of HBV-DNA above 20,000 IU/mL might suggest a higher risk 
of HCC.32 In our study, we used the cutoff value of 20,000 IU/mL 
to categorize groups. Nevertheless, the risks of HCC development 
was not significantly different between the IT-group and AVT-
group. Thus, it is hypothesized that if we used higher HBV-DNA 
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levels as the cutoff value to define the IT-phase, the long-term 
prognosis of patients with IT-phase would become favorable. 
Therefore, further large-scale studies are required to determine 
the association between viral titer concentrations and the risks of 
liver-related events.
Third, similar to HBV-DNA levels, we used 40 IU/L as the ALT 
cutoff value to define the IT-phase for patients. However, the 
overall similar results were maintained when we used cutoff val-
ues defined by AASLD (<30 IU/L for men and <19 IU/L for wom-
en) and KASL (<34 IU/L for men and <30 IU/L for women), re-
spectively (data not shown). Because serum levels of ALT and 
necroinflammatory activity of liver disease are not always associ-
ated,2,14 some patients requiring AVT might have been incorporat-
ed into IT-group.33 This issue signifies that another surrogate fac-
tor other than 40 IU/L to define the IT-phase is required in real 
practice.
In conclusion, our study showed that after excluding patients 
with an FIB-4 score of ≥1.45, the risk of HCC development was 
not significantly different between the IT-group and AVT-group. 
However, there were no events of HCC in the IT-group stringently 
defined by a lower FIB-4 index. Thus, early AVT intervention 
should be cautiously considered for this group, especially if pa-
tients have been expected of a low fibrotic burden. However, in 
the absence of solid criteria to signify an IT-phase in patients 
without histology, the optimal criteria required to select an appro-
priate candidate for early AVT intervention for patients with IT-
phase who would be at increasing risk of HCC should be investi-
gated in further large-scale, well-designed studies.
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